Atara Biotherapeutics, Inc. (ATRA)

Market Cap	65.66M
Revenue (ttm)	100.44M
Net Income (ttm)	-133.16M
Shares Out	5.76M
EPS (ttm)	-22.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,809
Open	10.43
Previous Close	9.93
Day's Range	9.86 - 11.47
52-Week Range	6.50 - 39.50
Beta	0.54
Analysts	Buy
Price Target	26.50 (+132.46%)
Earnings Date	Nov 12, 2024

About ATRA

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as we...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2014
• Employees: 225
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRA
• Website: https://www.atarabio.com

Financial Performance

In 2023, Atara Biotherapeutics's revenue was $8.57 million, a decrease of -86.51% compared to the previous year's $63.57 million. Losses were -$276.13 million, 20.9% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is $26.5, which is an increase of 132.46% from the latest price.

Price Target

$26.5

(132.46% upside)

Analyst Consensus: Buy